AR128001A1 - Anticuerpos anti-pilra, usos de estos y métodos y reactivos relacionados - Google Patents
Anticuerpos anti-pilra, usos de estos y métodos y reactivos relacionadosInfo
- Publication number
- AR128001A1 AR128001A1 ARP220103475A ARP220103475A AR128001A1 AR 128001 A1 AR128001 A1 AR 128001A1 AR P220103475 A ARP220103475 A AR P220103475A AR P220103475 A ARP220103475 A AR P220103475A AR 128001 A1 AR128001 A1 AR 128001A1
- Authority
- AR
- Argentina
- Prior art keywords
- pilra
- binding
- human
- ipsc
- antibodies
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 101001129851 Homo sapiens Paired immunoglobulin-like type 2 receptor alpha Proteins 0.000 abstract 7
- 102100031651 Paired immunoglobulin-like type 2 receptor alpha Human genes 0.000 abstract 7
- 210000004263 induced pluripotent stem cell Anatomy 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 241000282693 Cercopithecidae Species 0.000 abstract 1
- 101001129850 Homo sapiens Paired immunoglobulin-like type 2 receptor beta Proteins 0.000 abstract 1
- 241000282567 Macaca fascicularis Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 101000984191 Mus musculus Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000057139 human PILRB Human genes 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
En la presente se proporcionan anticuerpos anti-PILRA con la selectividad altamente deseable: que tienen una unión comparable a las proteínas PILRA humanas y cynomolgus, pero una unión mucho más débil a la proteína PILRB humana, así como una unión a las variantes PILRA G78 y R78. Los perfiles de unión y selectividad de los anticuerpos descritos en la presente permiten que se utilicen en estudios en animales (por ejemplo, monos) sin la necesidad de depender de una molécula sustituta y también cuando se trata a sujetos con cualquiera de las variantes de PILRA. En la presente se describen adicionalmente, por primera vez, los descubrimientos biológicos relacionados con PILRA y los efectos de la reducción de la señalización de PILRA en las células. Reivindicación 1: Un anticuerpo aislado o fragmento de unión a antígeno de este que se une específicamente a un receptor a tipo 2 similar a la inmunoglobulina emparejado de mono cynomolgus (cynoPILRA), en donde la afinidad de unión para cynoPILRA es al menos 2 veces mayor que la afinidad de unión para un receptor b tipo 2 similar a la inmunoglobulina emparejado humano (hPILRB). Reivindicación 67: Un método para tratar una enfermedad neurodegenerativa en un sujeto, que comprende administrarle al sujeto el anticuerpo aislado o fragmento de unión al antígeno de este de cualquiera de las reivindicaciones 1 a 59 o la composición farmacéutica de la reivindicación 61. Reivindicación 88: Una línea celular IPSC o célula madre pluripotente inducida por humanos modificada genéticamente (IPSC), en donde el IPSC se ha modificado para expresar dos copias del gen que codifica la variante R78 o la variante G78 de una proteína PILRA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163290930P | 2021-12-17 | 2021-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128001A1 true AR128001A1 (es) | 2024-03-20 |
Family
ID=85227410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103475A AR128001A1 (es) | 2021-12-17 | 2022-12-16 | Anticuerpos anti-pilra, usos de estos y métodos y reactivos relacionados |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR128001A1 (es) |
| TW (1) | TW202337906A (es) |
| WO (1) | WO2023114515A2 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009131632A1 (en) | 2008-04-14 | 2009-10-29 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
| WO2011100058A1 (en) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| WO2019126472A1 (en) * | 2017-12-22 | 2019-06-27 | Genentech, Inc. | Use of pilra binding agents for treatment of a disease |
| BR112022016368A2 (pt) * | 2020-02-18 | 2023-01-10 | Alector Llc | Anticorpos pilra e seus métodos de uso |
| EP4392448A2 (en) * | 2021-08-25 | 2024-07-03 | Alector LLC | Pilra antibodies and methods of use thereof |
-
2022
- 2022-12-16 AR ARP220103475A patent/AR128001A1/es unknown
- 2022-12-16 WO PCT/US2022/053245 patent/WO2023114515A2/en active Application Filing
- 2022-12-16 TW TW111148570A patent/TW202337906A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023114515A3 (en) | 2023-08-17 |
| WO2023114515A2 (en) | 2023-06-22 |
| TW202337906A (zh) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Geng et al. | The transcriptional coactivator TAZ regulates reciprocal differentiation of TH17 cells and Treg cells | |
| CL2021001986A1 (es) | Anticuerpos y receptores quiméricos de antígenos específicos para receptor 1 huérfano tipo receptor tirosina-cinasa (ror1). | |
| Yuan et al. | Tetrandrine ameliorates collagen-induced arthritis in mice by restoring the balance between Th17 and Treg cells via the aryl hydrocarbon receptor | |
| AR117774A2 (es) | Anticuerpos humanos que se unen al gen 3 de activación linfocitaria (lag-3) y los usos de estos | |
| CY1125092T1 (el) | Ιατρικη χρηση σχετικα με επεκταση τελομερους | |
| Leterrier et al. | Ankyrin G membrane partners drive the establishment and maintenance of the axon initial segment | |
| CL2008002153A1 (es) | Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r. | |
| DeSilva et al. | Expression of EAAT2 in neurons and protoplasmic astrocytes during human cortical development | |
| Pruitt et al. | Cdkn1b overexpression in adult mice alters the balance between genome and tissue ageing | |
| GT201000148A (es) | Anticuerpos antimesotelina y usos de los mismos | |
| Liebl et al. | Dimerization of visinin-like protein 1 is regulated by oxidative stress and calcium and is a pathological hallmark of amyotrophic lateral sclerosis | |
| Shi et al. | Retinoschisin facilitates the function of L-type voltage-gated calcium channels | |
| BR112018075692A2 (pt) | genes cln1 otimizados e cassetes de expressão e seu uso | |
| Oliveira-Fusaro et al. | P2X4 receptors on muscle macrophages are required for development of hyperalgesia in an animal model of activity-induced muscle pain | |
| NI202000051A (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
| BR112021016791A2 (pt) | Proteínas de ligação de antígenos que se ligam a bcma | |
| CO2021008204A2 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso | |
| EA202192252A1 (ru) | Высокоавидные т-клеточные рецепторы к wt1 и их применения | |
| Rovira et al. | Zebrafish Galectin 3 binding protein is the target antigen of the microglial 4C4 monoclonal antibody | |
| BR112017022205A2 (pt) | anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada | |
| AR128001A1 (es) | Anticuerpos anti-pilra, usos de estos y métodos y reactivos relacionados | |
| Nechanitzky et al. | Cholinergic control of Th17 cell pathogenicity in experimental autoimmune encephalomyelitis | |
| CL2023003218A1 (es) | Polipéptidos de unión a antígeno bma031 mejorados | |
| CO2021009689A2 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso. | |
| Udagawa et al. | Inwardly rectifying potassium channel Kir4. 1 is localized at the calyx endings of vestibular afferents |